The group's principal activities are to discover, develop and commercialize vaccines, antibiotics and novel anti-infectives for the prevention and treatment of infectious diseases. It is developing a certain commensal bacteria (commensals) as a means to deliver mucosal vaccines. Commensals are harmless bacteria that naturally inhabit the body's surfaces with different commensals inhabiting different mucosal surfaces. It is also developing veterinary vaccines and surface protein expression system. Its anti-infective programs are aimed at the increasingly serious problem of drug resistance and are designed to block the ability of bacteria to attach to human tissue. The group has research and development activities in Oregon state university and at the university of California, los angeles. On 23-May-2003, the group acquired all of the assets of plexus vaccine inc and assumed certain liabilities.
